{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T10:45:39Z","timestamp":1787222739915,"version":"build-2736575974"},"reference-count":46,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T00:00:00Z","timestamp":1596153600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.ejso.2020.07.011","type":"journal-article","created":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T01:39:33Z","timestamp":1595813973000},"page":"2147-2153","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["The association between active tumor volume, total lesion glycolysis and levels of S-100B and LDH in stage IV melanoma patients"],"prefix":"10.1016","volume":"46","author":[{"given":"E.A.","family":"Deckers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kruijff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.H.","family":"Brouwers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"van der Steen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.J.","family":"Hoekstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.F.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"V\u00e1llez Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.P.","family":"Wevers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ejso.2020.07.011_bib1","doi-asserted-by":"crossref","first-page":"e371","DOI":"10.1016\/S1470-2045(14)70072-5","article-title":"Systemic treatment for BRAF-mutant melanoma: where do we go next?","volume":"15","author":"Menzies","year":"2014","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.ejso.2020.07.011_bib2","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.ejso.2020.07.011_bib3","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1245\/s10434-013-2881-1","article-title":"Stage IV melanoma: completely resectable patients are scarce","volume":"20","author":"Wevers","year":"2013","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.ejso.2020.07.011_bib4","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/bjd.16347","article-title":"A\u00a0new era of proactive melanoma therapy: hit hard, hit early","volume":"178","author":"Haas","year":"2018","journal-title":"Br J Dermatol"},{"issue":"15","key":"10.1016\/j.ejso.2020.07.011_bib5","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1200\/JCO.2016.71.9393","article-title":"Conditional survival: an assessment of the prognosis of patients at time points after initial diagnosis and treatment of locoregional melanoma metastasis","volume":"35","author":"Haydu","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2020.07.011_bib6","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/CMR.0b013e3282f05039","article-title":"Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma","volume":"17","author":"Garbe","year":"2007","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ejso.2020.07.011_bib7","doi-asserted-by":"crossref","first-page":"w14279","DOI":"10.4414\/smw.2016.14279","article-title":"The updated swiss guidelines 2016 for the treatment and follow-up of cutaneous melanoma","volume":"146","author":"Dummer","year":"2016","journal-title":"Swiss Med Wkly"},{"key":"10.1016\/j.ejso.2020.07.011_bib8","unstructured":"NCCN clinical practice guidelines in oncology. https:\/\/www.nccn.org\/store\/login\/login.aspx?ReturnURL=https:\/\/Www.nccn.org\/professionals\/physician_gls\/pdf\/cutaneous_melanoma.pdf. Accessed november 2019."},{"key":"10.1016\/j.ejso.2020.07.011_bib9","unstructured":"Australian government, national health and medical research council. clinical practice guidelines for the management of melanoma in Australia and New Zealand. https:\/\/www.health.govt.nz\/system\/files\/documents\/publications\/melanoma-guideline-nov08-v2.pdf Accessed november 2019."},{"issue":"3","key":"10.1016\/j.ejso.2020.07.011_bib10","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1200\/JCO.2001.19.3.824","article-title":"Serum S-100b protein as a prognostic marker in malignant cutaneous melanoma","volume":"19","author":"Martenson","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2020.07.011_bib11","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/BF03032392","article-title":"Comparison of prognostic significance of serum 5-S-cysteinyldopa, LDH and S-100B protein in stage III-IV malignant melanoma","volume":"8","author":"Banfalvi","year":"2002","journal-title":"Pathol Oncol Res"},{"issue":"8","key":"10.1016\/j.ejso.2020.07.011_bib12","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1245\/s10434-013-2949-y","article-title":"S-100B: a stronger prognostic biomarker than LDH in stage IIIB-C melanoma","volume":"20","author":"Wevers","year":"2013","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"10.1016\/j.ejso.2020.07.011_bib13","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1245\/s10434-009-0629-8","article-title":"S-100B concentrations predict disease-free survival in stage III melanoma patients","volume":"16","author":"Kruijff","year":"2009","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2020.07.011_bib14","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/jso.25682","article-title":"S-100B as an extra selection tool for FDG PET\/CT scanning in follow-up of AJCC stage III melanoma patients","volume":"120","author":"Deckers","year":"2019","journal-title":"J\u00a0Surg Oncol"},{"issue":"5","key":"10.1016\/j.ejso.2020.07.011_bib15","first-page":"449","article-title":"Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma","volume":"63","author":"Kelderman","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ejso.2020.07.011_bib16","series-title":"AJCC cancer staging manual 8th","author":"Amin","year":"2017"},{"issue":"6","key":"10.1016\/j.ejso.2020.07.011_bib17","first-page":"472","article-title":"Melanoma staging: evidence-based changes in the american joint committee on cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"Ca - Cancer J Clin"},{"issue":"8","key":"10.1016\/j.ejso.2020.07.011_bib18","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1245\/s10434-018-6513-7","article-title":"Melanoma staging: American joint committee on cancer (AJCC) 8th edition and beyond","volume":"25","author":"Gershenwald","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2020.07.011_bib19","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00259-009-1297-4","article-title":"FDG PET and PET\/CT: EANM procedure guidelines for tumour PET imaging: version 1.0","volume":"37","author":"Boellaard","year":"2010","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"2","key":"10.1016\/j.ejso.2020.07.011_bib20","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","article-title":"FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0","volume":"42","author":"Boellaard","year":"2015","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"3","key":"10.1016\/j.ejso.2020.07.011_bib21","first-page":"14","article-title":"World medical association declaration of helsinki: ethical principles for medical research involving human subjects","volume":"81","author":"General Assembly of the World Medical Association","year":"2014","journal-title":"J\u00a0Am Coll Dent"},{"issue":"1","key":"10.1016\/j.ejso.2020.07.011_bib22","first-page":"1753","article-title":"Quantitative oncology molecularanalysis suite: accurate","volume":"59","author":"Boellaard","year":"2018","journal-title":"J\u00a0Nucl Med"},{"issue":"2","key":"10.1016\/j.ejso.2020.07.011_bib23","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1148\/radiol.14132807","article-title":"Repeatability of metabolically active tumor volume measurements with FDG PET\/CT in advanced gastrointestinal malignancies: a multicenter study","volume":"273","author":"Frings","year":"2014","journal-title":"Radiology"},{"issue":"1","key":"10.1016\/j.ejso.2020.07.011_bib24","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13550-018-0397-1","article-title":"Volume of interest delineation techniques for (18)F-FDG PET-CT scans during neoadjuvant extremity soft tissue sarcoma treatment in adults: a feasibility study","volume":"8","author":"Stevenson","year":"2018","journal-title":"EJNMMI Res"},{"issue":"1","key":"10.1016\/j.ejso.2020.07.011_bib25","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13550-018-0453-x","article-title":"Mapping heterogeneity in glucose uptake in metastatic melanoma using quantitative (18)F-FDG PET\/CT analysis","volume":"8","author":"de Heer","year":"2018","journal-title":"EJNMMI Res"},{"issue":"10","key":"10.1016\/j.ejso.2020.07.011_bib26","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.2165\/00003088-200544100-00004","article-title":"Quantification of lean bodyweight","volume":"44","author":"Janmahasatian","year":"2005","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"10.1016\/j.ejso.2020.07.011_bib27","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1245\/s10434-009-0629-8","article-title":"S-100B concentrations predict disease-free survival in stage III melanoma patients","volume":"16","author":"Kruijff","year":"2009","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2020.07.011_bib28","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1159\/000095034","article-title":"Detection of melanoma relapse: first comparative analysis on imaging techniques versus S100 protein","volume":"213","author":"Beyeler","year":"2006","journal-title":"Dermatology"},{"key":"10.1016\/j.ejso.2020.07.011_bib29","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1186\/1471-2407-11-328","article-title":"Role of serum S100B and PET-CT in follow-up of patients with cutaneous melanoma","volume":"11","author":"Peric","year":"2011","journal-title":"BMC Canc"},{"issue":"3","key":"10.1016\/j.ejso.2020.07.011_bib30","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ejso.2010.12.013","article-title":"The value of pre operative S-100B and SUV in clinically stage III melanoma patients undergoing therapeutic lymph node dissection","volume":"37","author":"Kruijff","year":"2011","journal-title":"Eur J Surg Oncol"},{"issue":"9","key":"10.1016\/j.ejso.2020.07.011_bib31","first-page":"18","article-title":"A\u00a0global review of melanoma follow-up guidelines","volume":"6","author":"Trotter","year":"2013","journal-title":"J\u00a0Clin Aesthet Dermatol"},{"issue":"4","key":"10.1016\/j.ejso.2020.07.011_bib32","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ejso.2015.12.010","article-title":"The predictive power of serum S-100B for non-sentinel node positivity in melanoma patients","volume":"42","author":"Damude","year":"2016","journal-title":"Eur J Surg Oncol"},{"issue":"7","key":"10.1016\/j.ejso.2020.07.011_bib33","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1200\/JCO.2005.03.5634","article-title":"Diagnostic performance of whole body dual modality 18F-FDG PET\/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients","volume":"24","author":"Reinhardt","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"28","key":"10.1016\/j.ejso.2020.07.011_bib34","doi-asserted-by":"crossref","first-page":"4774","DOI":"10.1200\/JCO.2008.20.1822","article-title":"Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment","volume":"27","author":"Bastiaannet","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2020.07.011_bib35","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00259-017-3740-2","article-title":"EANM\/EARL harmonization strategies in PET quantification: from daily practice to multicentre oncological studies","volume":"44","author":"Aide","year":"2017","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"9","key":"10.1016\/j.ejso.2020.07.011_bib36","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/RLU.0000000000002188","article-title":"Prognostic value of pretreatment metabolic PET parameters in cervical cancer patients with metabolic complete response after concurrent chemoradiotherapy","volume":"43","author":"Son","year":"2018","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.ejso.2020.07.011_bib37","first-page":"1","article-title":"Tumor heterogeneity on FDG PET\/CT and immunotherapy: an imaging biomarker for predicting treatment response in patients with metastatic melanoma","author":"Sanli","year":"2019","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.ejso.2020.07.011_bib38","first-page":"7","article-title":"Prognostic value of total lesion glycolysis and metabolic active tumor volume in non-small cell lung cancer","volume":"15","author":"Vanhove","year":"2018","journal-title":"Cancer Treat Res Commun"},{"issue":"3","key":"10.1016\/j.ejso.2020.07.011_bib39","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1159\/000106575","article-title":"S-100B and FDG-PET\/CT in therapy response assessment of melanoma patients","volume":"215","author":"Strobel","year":"2007","journal-title":"Dermatology"},{"issue":"9","key":"10.1016\/j.ejso.2020.07.011_bib40","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1007\/s00259-007-0403-8","article-title":"Tumour assessment in advanced melanoma: value of FDG-PET\/CT in patients with elevated serum S-100B","volume":"34","author":"Strobel","year":"2007","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"9","key":"10.1016\/j.ejso.2020.07.011_bib41","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1038\/bjc.2015.361","article-title":"Serum lactate dehydrogenase and survival following cancer diagnosis","volume":"113","author":"Wulaningsih","year":"2015","journal-title":"Br J Canc"},{"issue":"36","key":"10.1016\/j.ejso.2020.07.011_bib42","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2020.07.011_bib43","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1177\/172460080502000106","article-title":"Comparison of four different assays for determination of serum S-100B","volume":"20","author":"Smit","year":"2005","journal-title":"Int J Biol Markers"},{"issue":"23\u201324","key":"10.1016\/j.ejso.2020.07.011_bib44","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/j.cca.2011.07.020","article-title":"Comparison of three assays for quantifying S-100B in serum","volume":"412","author":"Erickson","year":"2011","journal-title":"Clin Chim Acta"},{"issue":"1","key":"10.1016\/j.ejso.2020.07.011_bib45","first-page":"56","article-title":"Serum S-100B protein and stage of cutaneous melanoma: a prospective study","volume":"127","author":"Brouard","year":"2000","journal-title":"Ann Dermatol Venereol"},{"issue":"6","key":"10.1016\/j.ejso.2020.07.011_bib46","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1245\/s10434-019-07311-0","article-title":"False-positive results and incidental findings with annual CT or PET\/CT surveillance in asymptomatic patients with resected stage III melanoma","volume":"26","author":"Nijhuis","year":"2019","journal-title":"Ann Surg Oncol"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798320306375?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798320306375?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:35:19Z","timestamp":1760060119000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798320306375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":46,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S0748798320306375"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2020.07.011","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The association between active tumor volume, total lesion glycolysis and levels of S-100B and LDH in stage IV melanoma patients","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2020.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}